Qiagen snares sequencing tech in $60M deal
Qiagen has bought out the Biosystems division of Biotage, snaring new sequencing technology in a deal worth $53 million in cash and up to $7 million in milestones over the next four years. Qiagen also bought Biotage's shares in Corbett Life Science.
"Qiagen has an excellent molecular assay and also epigenetic portfolios which perfectly fits together with our PyroMark instruments," says Torben JArgensen, CEO of Biotag. "Many of our customers are Qiagen customers as well. In addition, Qiagen's technology leadership in molecular sample and assay technologies, its global reach and extensive marketing, combined with strong relationships with researchers and leading laboratories around the world, bring exciting opportunities for Biosystems. "
- here's the release for more
Related Articles:
Qiagen inks deal to buy Corbett
Digene agrees to $1.6B takeover by Qiagen (June 2007)
Qiagen acquires Genaco in $40M deal (Oct. 2006)
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
